91 related articles for article (PubMed ID: 9198724)
1. [Direct thrombin inhibitors].
Bornkessel B
Med Monatsschr Pharm; 1997 Apr; 20(4):86-9. PubMed ID: 9198724
[No Abstract] [Full Text] [Related]
2. Development of direct thrombin inhibitors in comparison with glycosaminoglycans.
Markwardt F
Semin Thromb Hemost; 2001 Oct; 27(5):523-30. PubMed ID: 11668423
[TBL] [Abstract][Full Text] [Related]
3. Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance.
Verstraete M
Thromb Haemost; 1997 Jul; 78(1):357-63. PubMed ID: 9198179
[No Abstract] [Full Text] [Related]
4. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists.
Harker LA; Hanson SR; Kelly AB
Thromb Haemost; 1995 Jul; 74(1):464-72. PubMed ID: 8578508
[No Abstract] [Full Text] [Related]
5. Clinical trials of conjunctive anticoagulant strategies in thrombolysis.
Kleiman NS
Coron Artery Dis; 1996 Jul; 7(7):508-15. PubMed ID: 8913678
[No Abstract] [Full Text] [Related]
6. Comparative pharmacology of site directed antithrombin agents. Implication in drug development.
Callas D; Fareed J
Thromb Haemost; 1995 Jul; 74(1):473-81. PubMed ID: 8578509
[TBL] [Abstract][Full Text] [Related]
7. Direct thrombin inhibition superior to heparin during and after thrombolysis: dose, duration, and drug.
Chesebro JH
Circulation; 1997 Oct; 96(7):2118-20. PubMed ID: 9337177
[No Abstract] [Full Text] [Related]
8. Production and clinical development of a Hansenula polymorpha-derived PEGylated hirudin.
Avgerinos GC; Turner BG; Gorelick KJ; Papendieck A; Weydemann U; Gellissen G
Semin Thromb Hemost; 2001 Aug; 27(4):357-72. PubMed ID: 11547358
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of direct thrombin inhibitors during invasive procedures.
Hermann JP; Kutryk MJ; Serruys PW
Thromb Haemost; 1997 Jul; 78(1):367-76. PubMed ID: 9198181
[No Abstract] [Full Text] [Related]
10. Hirudin and thrombosis prophylaxis.
Turpie AG
Lancet; 1996 Mar; 347(9002):632-3. PubMed ID: 8596373
[No Abstract] [Full Text] [Related]
11. Specific antithrombins in the context of current treatment for acute coronary syndromes.
Fox KA
Eur Heart J; 1999 Nov; 20(21):1519-21. PubMed ID: 10529315
[No Abstract] [Full Text] [Related]
12. Hirudin-based synthetic peptides as inhibitors of thrombin.
Chari S; Chauhan VS
Semin Thromb Hemost; 1994; 20(4):315-8. PubMed ID: 7899860
[No Abstract] [Full Text] [Related]
13. Thrombin functions and antithrombotic intervention.
Fenton JW
Thromb Haemost; 1995 Jul; 74(1):493-8. PubMed ID: 8578512
[No Abstract] [Full Text] [Related]
14. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes.
Maraganore JM; Adelman BA
Coron Artery Dis; 1996 Jun; 7(6):438-48. PubMed ID: 8889359
[TBL] [Abstract][Full Text] [Related]
15. Modulating platelet function with selective thrombin inhibitors.
Verstraete M
Haemostasis; 1996 Oct; 26 Suppl 4():70-7. PubMed ID: 8979113
[TBL] [Abstract][Full Text] [Related]
16. Direct thrombin inhibitors in acute coronary syndromes.
Jang IK
Lancet; 2002 Aug; 360(9331):491-2; author reply 492. PubMed ID: 12241752
[No Abstract] [Full Text] [Related]
17. Potential advantages of direct-acting thrombin inhibitors.
Philippides GJ; Loscalzo J
Coron Artery Dis; 1996 Jul; 7(7):497-507. PubMed ID: 8913677
[No Abstract] [Full Text] [Related]
18. Hirunorms, novel hirudin-like direct thrombin inhibitors.
Cappiello M; Vilardo PG; Del Corso A; Mura U
Gen Pharmacol; 1998 Apr; 30(4):565-8. PubMed ID: 9522176
[TBL] [Abstract][Full Text] [Related]
19. Antithrombins and the importance of good control.
Tideman PA
Aust N Z J Med; 1999 Jun; 29(3):444-51. PubMed ID: 10868518
[TBL] [Abstract][Full Text] [Related]
20. [Use of new thrombin inhibitors in medical practice].
Blaya C; Prati C; Boneti C; Bonamigo DR; Krumenauer RC; Rosito GA
Arq Bras Cardiol; 1998 Aug; 71(2):163-7. PubMed ID: 9816691
[No Abstract] [Full Text] [Related]
[Next] [New Search]
